Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592835 | 1.00 | F10 (0.53) | F10ACKR3KDM4EPKMNAMPT | |
| SCHEMBL3447616 | 0.90 | ACKR3 (0.45) | F10ACKR3KDM4EPKMNAMPT | |
| SCHEMBL4592698 | 0.90 | ACKR3 (0.45) | F10ACKR3KDM4EPKMNAMPT | |
| SCHEMBL3447111 | 0.89 | ACKR3 (0.48) | F10ACKR3KDM4EPKMNAMPT | |
| SCHEMBL4591552 | 0.86 | F10 (0.57) | F10F2 | |
| SCHEMBL4592555 | 0.86 | F10 (0.57) | F10F2 | |
| SCHEMBL3448759 | 0.82 | F10 (0.51) | F10F2 | |
| SCHEMBL3449326 | 0.80 | ACKR3 (0.65) | F10ACKR3KDM4EPKMNAMPT | |
| SCHEMBL3449327 | 0.80 | ACKR3 (0.65) | F10ACKR3KDM4EPKMNAMPT | |
| SCHEMBL20615620 | 0.79 | KDM4E (0.64) | F10ACKR3KDM4EPKMNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | F10 4/4885ACKR3 568/4885KDM4E 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.